miRNA-Based Therapy Offers New Hope for Triple Negative Breast Cancer Patients

Researchers have identified microRNAs (miRNAs) as key molecular tools in personalized medicine, positioning them as potential therapeutic options for Triple Negative Breast Cancer (TNBC) patients. A study based on big data analysis of Gene Expression Omnibus (GEO) datasets has revealed that certain miRNAs are downregulated in TNBC samples compared to normal breast tissue samples. The study suggests that strategies aimed at restoring the expression of these miRNAs could offer novel therapeutic approaches for TNBC patients.

Key Takeaways:

• The study identified 353 miRNAs that were differentially expressed in TNBC samples compared to normal breast tissue samples, with 110 miRNAs upregulated and 243 miRNAs downregulated.
• The top five downregulated miRNAs were miR-204, miR-6068, miR-139, miR-26a, and miR-215, which are involved in various hallmarks of cancer.
• Validation using quantitative real-time PCR (qRT-PCR) analysis showed that miR-204, miR-139, and miR-26a were significantly downregulated in TNBC cell lines compared to non-tumorigenic cells.
• Kaplan-Meier analysis showed that the survival rate of patients with low miR-204 expression was significantly lower compared to the miR-204 upregulated group.
• The study concluded that strategies aimed at restoring the expression of miR-204 through miRNA replacement therapies could offer novel therapeutic approaches for TNBC patients.

Statistics:

• 353 miRNAs were differentially expressed in TNBC samples compared to normal breast tissue samples.
• 110 miRNAs were upregulated in TNBC samples, while 243 miRNAs were downregulated.
• The top five downregulated miRNAs were miR-204, miR-6068, miR-139, miR-26a, and miR-215.
• Kaplan-Meier analysis showed a significant difference in survival rates between patients with low miR-204 expression and those with high miR-204 expression.
• 94 TNBC-positive and 40 normal tissue samples were analyzed using DESeq2 software.

Sources:

• Sivakumar Krishnankutty Chandrika et al. Tumor Suppressor miRNA-based Signatures in Triple Negative Breast Cancer: A Study Based on Big Data Analysis of Gene Expression Omnibus (GEO) Datasets and Its Validation. Asian Pacific Journal of Cancer Prevention, 2025;26(6):2087-2095.
• NewsRx. Data on miRNA-Based Therapy Reported by Sivakumar Krishnankutty Chandrika and Colleagues [Tumor Suppressor miRNA-based Signatures in Triple Negative Breast Cancer: A Study Based on Big Data Analysis of Gene Expression Omnibus (GEO) Datasets and ...]. Information Technology Newsweekly. July 8, 2025; p 215.